ostavax is a vaccine developed and marketed by Merck & Co. to prevent shingles, an extremely painful rash similar to chickenpox. The vaccine was approved by the FDA in May 2006 for adults age 50 or older. The vaccine was financially very successfully for Merck, earning the company billions of dollars.
Unfortunately, despite being very profitable, Zostavax caused many who were vaccinated extremely serious complications. Thousands of Zostavax-related complications and injuries were reported to the FDA, ranging from actually causing shingles to post-herpetic neuralgia, nerve damage, vision loss, hearing loss, vertigo/imbalance, heart attacks, strokes, and even death. These injuries have been seen as early as days after the vaccine and as late as six months after. Based on the frequency and severity of the complications, U.S. Center for Disease Control has recommended that Americans ask their pharmacist for Shingrix, a safer and more effective shingles vaccine, instead of Zostavax.
If you or a loved one were vaccinated for shingles with Zostavax and experienced a serious complication, contact us at 804.466.4412. You may be eligible for compensation.
Kincheloe, Litzenburg & Pendleton, PLLC is pleased to announce that Tim Litzenburg and the firm have been named to the Zostavax litigation national plaintiff’s steering committee.
Kincheloe, Litzenburg & Pendleton, PLLC is also pleased to announce that Tim Litzenburg and the firm have been named to the Zostavax litigation national plaintiff’s steering committee.